COMP <GO>
JBTM vs TMO // EV/EBITDA & P/E VALUATION
JBT Marel Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: JBTM 5
— TMO 10
▲ EV/EBITDA & P/E VALUATION LEADER: JBTM
LAST: $109.17 (-1.15%) • MKT CAP: $5.73B
valuation
21.0x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JBTM VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JBTM | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.10% | 41.00% | -5.90 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.60% | 9.30% | -6.70 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.0x | 30.4x | -9.40 | JBTM | /valuation <GO> |
| Free Cash Flow Yield | -3.99% | 2.40% | -6.39 | TMO | /fcf-yield <GO> |
| Operating Margin | 5.00% | 17.40% | -12.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | -1.30% | 15.10% | -16.40 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 121.30% | 3.90% | +117.40 | JBTM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.36% | 0.24% | +0.12 | JBTM | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.66 | 4.50 | -2.84 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.70% | +0.20 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.0 | 59.1 | -8.16 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.94 | +0.05 | JBTM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 36.3x | -18.30 | JBTM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.73B | $262.22B | -$256.49B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JBTM REV | TMO REV | JBTM GROSS % | TMO GROSS % | JBTM FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.80B | $44.56B | 35.1% | 44.0% | -$227.5M | $6.29B |
| FY 2024 | $1.72B | $42.88B | 36.5% | 44.0% | $18.4M | $7.27B |
| FY 2023 | $1.66B | $42.86B | 44.0% | 44.0% | $577.6M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JBTM // BETA 0.99
TMO // BETA 0.94